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ABSTRACT 
Arterial medial calcification (AMC) is thought to share some outward similarities to skeletal mineralisation 
and has been associated with the transdifferentiation of vascular smooth muscle cells (VSMCs) to an 
osteoblast-like phenotype.  ATP and UTP have previously been shown to inhibit bone mineralisation.  
This investigation compared the effects of extracellular nucleotides on calcification in VSMCs with those 
seen in osteoblasts.  ATP, UTP and the ubiquitous mineralisation inhibitor, pyrophosphate (PPi), dose 
dependently inhibited VSMC calcification by ≤85%.  Culture of VSMCs in calcifying conditions was 
associated with an increase in apoptosis; treatment with ATP, UTP and PPi reduced apoptosis to levels 
seen in non-calcifying cells.  Extracellular nucleotides had no effect on osteoblast viability. Basal alkaline 
phosphatase (TNAP) activity was over 100-fold higher in osteoblasts than VSMCs.   ATP and UTP 
reduced osteoblast TNAP activity (≤50%) but stimulated VSMC TNAP activity (≤88%). The effects of 
extracellular nucleotides on VSMC calcification, cell viability and TNAP activity were unchanged by 
deletion or inhibition of the P2Y2 receptor.  Conversely, the actions of ATP/UTP on bone mineralisation 
and TNAP activity were attenuated in osteoblasts lacking the P2Y2 receptor.  Ecto-nucleotide 
pyrophosphatase/phosphodiesterase 1 (NPP1) hydrolyses ATP and UTP to produce PPi.  In both 
VSMCs and osteoblasts, deletion of NPP1 blunted the inhibitory effects of extracellular nucleotides 
suggesting involvement of P2 receptor independent pathways.  Our results show that although the 
overall functional effect of extracellular nucleotides on AMC and bone mineralisation is similar there are 
clear differences in the cellular mechanisms mediating these actions.   
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INTRODUCTION 
Vascular calcification is a common consequence of ageing, atherosclerosis, diabetes and chronic kidney 
disease.  It is the pathological deposition of calcium phosphate mineral, usually as hydroxyapatite, in the 
medial and/or intimal layer of the arteries and heart valves.  Arterial medial calcification (AMC) refers to 
the calcification that occurs within the tunica media of blood vessels and is characterised by increased 
vessel stiffness and reduced blood flow (Young et al., 1993). Traditionally, AMC was thought to be a 
passive process caused by high serum levels of phosphate and calcium.  However, it is now accepted 
that it is a complex cell-mediated process that shares some similarities with the process of physiological 
bone formation.  Specifically, AMC is thought to involve the loss of calcification inhibitors (e.g. 
pyrophosphate (PPi), osteopontin, fetuin A), gain of calcification inducers (e.g. alkaline phosphatase 
(TNAP)) and increased apoptosis (Proudfoot et al., 2000; Zhu et al., 2012).  Whilst many cell types can 
contribute towards the development of AMC, vascular smooth muscle cells (VSMCs) are thought to be 
the major cell type involved (Narisawa et al., 2007; Zhu et al., 2011).  Within a calcifying environment 
(high phosphate), VSMCs can undergo a phenotypic transdifferentiation to take on characteristics usually 
associated with bone-forming osteoblasts (Shroff and Shanahan, 2007; Zhu et al., 2011). 
ATP has long been recognized for its role in intracellular energy metabolism; however, it is also an 
important extracellular signalling molecule. ATP and related compounds (UTP, ADP, UDP) act via 
purinergic P2 receptors to regulate cell proliferation, differentiation, survival and function in many tissues 
(Burnstock, 2007). The P2 receptor family is made up of seven P2X ion channels (P2X1-7) and eight 
P2Y G-protein coupled receptors (P2Y1,2,4,6,11-14) (Abbracchio and Burnstock, 1994; Burnstock and 
Kennedy, 1985). 
Purinergic signalling plays a number of roles in the cardiovascular system (see review (Burnstock and 
Ralevic, 2014)).  VSMCs express multiple P2 receptor subtypes (Wang et al., 2002) and in recent years 
several investigations have examined the role of purinergic signalling in the different forms of vascular 
calcification (Fish et al., 2013).  However, they provide conflicting evidence as to whether extracellular 
nucleotides are harmful or protective.  P2Y2 receptor mediated signalling has been shown to promote the 
survival of aortic valve interstitial cells and protect against aortic valve calcification (Cote et al., 2012) and 
arterial intimal calcification (Qian et al., 2017).  Additionally, a biochemical study showed that ATP 
inhibited calcium phosphate deposition in rat VSMCs (Villa-Bellosta and Sorribas, 2013). In contrast, 
activation of P2YRs by Up4A (a non-selective P2R agonist) has been reported to enhance VSMC 
calcification (Schuchardt et al., 2012).   
Once released extracellular nucleotides are rapidly broken down by ecto-nucleotidases to limit their 
actions to cells within close proximity of the release site. PPi, a ubiquitous and potent inhibitor of 
calcification (Fleisch and Bisaz, 1962), is generated when nucleotide triphosphates are hydrolysed by 
ecto-nucleotide pyrophosphatase/phosphodiesterases (NPPs). VSMCs express many ecto-
nucleotidases, including NPP1, and can release ATP in a controlled manner (Prosdocimo et al., 2009; 
Prosdocimo et al., 2010; Villa-Bellosta et al., 2011). Accumulating evidence now suggests that the 
hydrolysis of locally released ATP by NPP1 is the major source of extracellular PPi (Orriss et al., 2016; 
Prosdocimo et al., 2009). This PPi can then act locally to regulate the level of calcification.  Consistent 
with this, NPP1 knockout mice (Enpp1-/-) display extensive ectopic calcification in a variety of soft tissues 
including the aorta, kidney, cartilage, ear pinna and whisker vibrissae (Hajjawi et al., 2014; Johnson et 
al., 2003; Mackenzie et al., 2012).  Furthermore, mutations in the gene encoding NPP1 lead to the 
recessive condition Generalised Arterial Calcification of Infancy (GACI) which is characterised by 
extensive vascular calcification (Rutsch et al., 2001).   
The regulation of bone formation by extracellular nucleotides has been widely studied often with 
conflicting results (see reviews (Burnstock et al., 2013; Gartland et al., 2012; Noronha-Matos and 
Correia-de-Sa, 2016; Orriss, 2015)).  Activation of several P2 receptors (e.g. P2Y2, P2X1, P2X7) has 
been shown to both inhibit and promote bone mineralisation (Hoebertz et al., 2002; Noronha-Matos et 
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al., 2014; Orriss et al., 2012a; Orriss et al., 2007; Panupinthu et al., 2007; Xing et al., 2014).  We have 
previously reported that ATP and UTP selectively inhibit the mineralisation of the organic matrix and 
TNAP expression and activity (Orriss et al., 2007).  These actions are due to both P2 receptor mediated 
signalling and also direct hydrolysis by NPP1 to produce PPi (Orriss et al., 2012a; Orriss et al., 2013; 
Orriss et al., 2007).  Recently, we also showed that activation of the P2Y2 receptor exerts some of its 
effects on bone mineralisation indirectly by promoting the release of ATP from osteoblasts (Orriss et al., 
2017). 
The aim of this study was to investigate the effects of extracellular nucleotides on AMC and, given the 
apparent similarities to bone mineralisation, to compare any functional effects to those seen in 
osteoblasts.   Established in vitro mouse models of AMC and bone formation were used to determine the 
cellular mechanisms mediating these actions.  Since the inhibitory effects of ATP and UTP on bone 
mineralisation involve both P2 receptor dependent and independent signalling we examined both 
pathways in parallel.   
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METHODS 
Reagents 
All tissue culture reagents were purchased from Life Technologies (Paisley, UK); unless mentioned, all 
chemicals were purchased from Sigma Aldrich (Poole, UK).  The selective P2Y2 receptor antagonist, 
ARC118935XX, was obtained from Tocris Bioscience (Bristol, UK). 
Animals 
Mice lacking the P2Y2 receptor gene (P2Y2R
-/-) were obtained from Jackson Laboratories (Bar Harbor, 
Maine, USA). The generation and characterisation of P2Y2R
-/- mice, which are on a C57BL/6J 
background, has been previously described (Homolya et al., 1999).  Animals were bred from 
homozygote (P2Y2R
-/-) and parental strain wildtype (P2Y2R
+/+) breeding pairs. The generation and 
characterisation of mice lacking NPP1 (Enpp1-/-), which are on a 129Sv/TerJ genetic background, has 
previously been described (Sali et al., 1999). Animals were bred from heterozygote (Enpp1+/-) breeding 
pairs.  All mice were housed under standard conditions with free access to food and water. All 
procedures complied with the UK animals (Scientific Procedures) Act 1986 and were reviewed and 
approved by the Royal Veterinary College Research Ethics Committee.  
Vascular smooth muscle cell (VSMC) calcification assay  
Primary VSMCs were isolated from aortas of P2Y2R
-/- or Enpp1-/- mice and their corresponding wildtypes 
(P2Y2R
+/+ or Enpp1+/+). After removal of the adventitia, the aorta was opened to expose the endothelial 
layer under a dissection microscope.  Tissues from 6-8 animals were pooled and incubated with trypsin 
(0.25% w/v) for 10 minutes to remove any remaining adventitia and endothelium. Tissues were incubated 
overnight in alpha Minimum Essential Medium, supplemented with 10% foetal calf serum (FCS), 100U/ml 
penicillin, 100µg/ml streptomycin and 0.25µg/ml amphotericin (complete mixture abbreviated to αMEM) 
before being digested with 425U/ml collagenase type II (Worthington Biomedical Corporation, Lakewood, 
USA) for 5 hours. Isolated VSMCs were expanded in T25 tissue culture flasks in a humidified 
atmosphere of 5% CO2-95% air at 37C until confluent. Following seeding into 24-well plates at a density 
of 2.5 x 104 cells/well, VSMCs were cultured in control (αMEM only) or calcifying medium (αMEM + 2mM 
phosphate) for up to 14 days, with half medium changes every 3 days. Cells were treated with 1-100µM 
extracellular nucleotides (ATP, ADP, UTP, UDP) or pyrophosphate (PPi) for the duration of the culture.  
The selective P2Y2 receptor antagonist, ARC118935XX, was used to confirm results obtained with 
P2Y2R
-/- cells. 
Aortic ring calcification assay 
Aortas were isolated from P2Y2R
+/+ or P2Y2R
-/- mice and the adventitia layer removed.  The vessels were 
cut into 2-3mm rings and cultured overnight in serum free αMEM.  After 24 hours, the rings were 
transferred to calcification medium (αMEM plus 2.5mM phosphate and 2.7mM calcium chloride).  Aortic 
rings were cultured for a further 9 days with half medium changes every 3 days. 
Determination of VSMC and aortic ring calcification 
Calcifying VSMCs or aortic rings were washed twice with phosphate buffered saline (PBS) and incubated 
with 0.6M HCl at room temperature for 24 hours.  Calcium content was measured colorimetrically by 
stable interaction with o-cresolphthalein using a commercially available kit (Sigma-Adrich, Poole, UK) 
and corrected for total protein concentration using the Bradford assay.  Calcium deposition was 
visualised by alizarin red staining of VSMC cell layers as previously described (Taylor et al., 2014). 
Osteoblast bone formation assay 
Osteoblasts were isolated from the calvariae of 3-5 day old mice by trypsin/collagenase digestion as 
previously described (Orriss et al., 2014; Orriss et al., 2012b; Taylor et al., 2014).  Cells were obtained 
from P2Y2R
-/-, P2Y2R
+/+, Enpp1-/- or Enpp1+/+ animals.  Following isolation, cells were resuspended in 
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αMEM and cultured for 2-4 days in a humidified atmosphere of 5% CO2-95% air at 37C in 75 cm
2 flasks 
until fully confluent.  Cells were sub-cultured into 6-well trays in αMEM supplemented with 2mM -
glycerophosphate and 50g/ml ascorbic acid, with half medium changes every 3 days. Cells were treated 
with 1-100µM ATP, UTP or PPi for the duration of the culture.   
To assess bone formation, experiments were terminated by fixing the cells in 2.5% glutaraldehyde for 5 
minutes. Cell culture plates were imaged at 800 dpi using a flat-bed scanner (Epson Perfection 4990 
Photo) and the total area of bone nodules formed was quantified by image analysis, as described 
previously (Orriss et al., 2012b). Cell layers were stained with alizarin red for microscopy. 
Analysis of P2 receptor gene expression by real time PCR 
VSMCs were cultured in control or calcification medium for 14 days.  RNA was extracted using RNeasy 
total RNA (Qiagen Ltd, Crawley, UK), according to the manufacturer’s instructions.  RNA was quantified 
and reverse transcribed as previously described (Mackenzie et al., 2014).  Levels of mRNA expression 
were measured using the SYBR green detection method (Roche, East Sussex, UK) as previously 
reported (Staines et al., 2014).  Data are presented as the fold change in expression in calcifying VSMCs 
relative to control cells.  Primer sequences are shown in table 1. 
Cell viability assay   
VSMCs and osteoblasts were cultured for 14 days in medium supplemented with ATP, UTP or PPi (1-
100µM). Cell number and viability was determined using the CytoTox 96® colorimetric cytotoxicity assay 
(Promega UK, Southampton UK), as described previously (Orriss et al., 2012a). Cell supernatants were 
collected to determine medium LDH levels (cell viability).   To establish total cellular LDH levels, cells 
were lysed with 1% Triton X-100 in water (lysis buffer, 15µl/ml of medium) for 1 hour. The LDH content of 
the supernatants and cell lysates were measured colorimetrically (490nm) as per manufacturer’s 
instructions.  A standard curve for determination of cell numbers was constructed using cells seeded at 
102 to 106/well. Cell viability (shown as percentage of dead cells) was calculated by expressing medium 
LDH as a percentage of the total cellular LDH. 
Quantification of apoptosis by flow cytometry 
VSMCs plated in 24-well trays were cultured in control or calcification medium (± treatment) for 7 days. 
Apoptosis was assessed via flow cytometry using an annexin V antibody conjugated to fluorescein (Life 
Technologies, Paisley, UK), as per manufacturer’s instructions. Briefly, cells were detached using trypsin 
(0.25%) and resultant pellet washed in ice cold PBS. This suspension was centrifuged and resuspended 
in 1X annexin-binding buffer (Life Technologies, Paisley, UK). A sample of this suspension was 
incubated with the annexin V antibody for 15 minutes, after which, analysed using a BD FACSCanto II 
Flow Cytometer (Becton, Dickinson and Company, Oxford, UK). Data was processed to calculate 
percentage apoptosis using Flowing Software (version 2.5.1) (Turku University, Finland). 
Determination of TNAP activity 
VSMCs and osteoblasts VSMCs were cultured with 1-100µM ATP, UTP or PPi for 14 days.  TNAP 
activity was measured in P2Y2R
-/-, Enpp1-/- or wildtype (P2Y2R
+/+ / Enpp1+/+) cell lysates using a 
colorimetric assay (Anaspec, CA, USA), as previously described (Orriss et al., 2012a).  TNAP activity 
was normalised to cell protein using the Bradford assay.     
Histology 
Histological analysis was performed on aortas obtained from 24-week old male P2Y2R
+/+ or P2Y2R
-/-mice. 
Tissues were fixed in 10% neutral buffered formalin and embedded in paraffin wax blocks.  Serial 
sections were cut every 5µm and mounted onto slides.  Before staining, the samples were de-
paraffinised using xylene, then rehydrated through a series of decreasing ethanol solutions and finally 
water. Slides were stained with haematoxylin and eosin (H&E) to examine cell morphology and alizarin 
red to visualise vascular calcification.  
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Statistical analysis 
Data were analysed using GraphPad Prism 6 software (San Diego, CA).  Statistical comparisons were 
made using one-way or two-way analysis of variance (ANOVA) with a post-hoc Bonferroni correction for 
multiple comparisons.  Results are expressed as means ± SEM for 6 replicates and are representative of 
experiments performed at least three times using cells or tissues obtained from different animals. 
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RESULTS 
P2 receptor expression is increased in calcifying VSMCs 
Analysis of mRNA expression revealed that mouse VSMCs express multiple P2 receptor subtypes 
including all the P2X receptors and the majority of the P2Y receptors (Fig. 1A).  Expression of the P2X1, 
P2X2, P2X4, P2X5, P2X6 and P2Y2 receptors was increased up to 3-fold in calcifying VSMCs compared 
to control VSMCs (Fig.1A). 
ATP, UTP and PPi inhibit VSMC calcification 
ATP (≥10µM) and UTP (≥1µM) dose dependently inhibited VSMC calcification by up to 80% (Fig. 1B, 
1C, 1G). UTP was more potent at exerting inhibitory actions from 1µM.  ADP and UDP had no effect at 
any of the concentrations tested (Fig. 1D, 1E, 1G).  The ubiquitous mineralisation inhibitor, PPi (≥10µM), 
reduced VSMC calcification up to 85% (Fig. 1F, 1G). Representative images in Fig. 1G show the 
inhibitory effects of 10µM ATP, UTP or PPi on calcification in mouse VSMC cultures. 
ATP, UTP and PPi increase VSMC viability and decrease apoptosis 
In calcifying VSMCs, treatment with ATP, UTP and PPi (≥10µM) decreased the percentage of dead cells 
present by up to 75%, 60% and 80%, respectively (Fig. 2A-2C).  ATP and UTP had no effect on 
osteoblast cell viability (Fig. 2D, 2E).  PPi at the highest dose (100µM) caused a 45% increase in 
osteoblast cell death. 
The level of apoptosis was increased up to 2.3-fold in calcifying VSMCs compared to control VSMCs 
(Fig 2G-2I).  Treatment with ATP, UTP and PPi (≥10µM) decreased the level of apoptosis in calcifying 
cells to the level seen in control VSMCs (Fig 2G-2I). 
The effect of ATP, UTP and PPi on TNAP activity in calcifying VSMCs and osteoblasts 
ATP and UTP (≥1µM) increased VSMC TNAP activity by up to 88% and 50%, respectively (Fig. 3A, 3B).  
PPi, (≥1µM), which is a substrate for TNAP, dose dependently stimulated enzyme activity by up to 80% 
(Fig. 3C). In contrast, ATP and UTP (≥1µM) inhibited osteoblast TNAP activity by up to 50% (Fig. 3D, 
3E).  PPi had no effect on TNAP activity in osteoblasts (Fig. 3F). It should also be noted that the basal 
TNAP activity of mineralising osteoblasts was at least 100-fold higher than that of a calcifying VSMCs 
(Fig. 3). 
The P2Y2 receptor does not mediate the effects of ATP & UTP on VSMC calcification 
Deletion of the P2Y2 receptor had no effect on the basal level of calcification in VSMC or aortic ring 
cultures (Fig. 4A, 4B).  The inhibitory effects of ATP and UTP on calcification were unchanged in P2Y2R
-
/- VSMCs (Fig. 4C, 4D).  The selective P2Y2 receptor antagonist, ARC118935XX, also failed to attenuate 
the inhibitory effects of UTP (Fig. 4E).  Isolated aortas from 24-week old P2Y2R
+/+ and P2Y2R
-/- mice 
showed no obvious differences in structure or cell morphology (Fig. 4F). Alizarin red staining revealed no 
spontaneous calcium deposition within any of the arterial layers (Fig. 4F). Representative images shown 
are from the descending aorta.  The effects of ATP and UTP on VSMC cell viability and TNAP activity 
were also unaffected by the deletion of the P2Y2 receptor (Fig. 4G-4J). 
Reduced inhibitory effects of ATP and UTP on bone mineralisation in P2Y2R
-/- osteoblasts 
ATP (≥10µM) and UTP (≥1µM) dose dependently reduced bone mineralisation in P2Y2R
+/+ osteoblasts 
by up to 80% (Fig. 5A, 5B, 5E). The overall level of mineralised bone nodule formation was up to 60% 
higher in P2Y2R
-/- cells compared to P2Y2R
+/+.  In P2Y2R
-/- osteoblasts, the effects of ATP and UTP were 
only observed at 100µM making them 10-fold and 100-fold less potent at inhibiting bone mineralisation, 
respectively (Fig. 5A, 5B, 5E).  Representative whole well scans (unstained) and phase contrast 
microscopy images (alizarin red stained) of osteoblast cell layers show the reduced inhibitory effects of 
ATP and UTP in P2Y2R
-/- osteoblasts. They also illustrate the increased level of bone formation in 
P2Y2R
-/- cells (Fig. 5E). 
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The inhibitory effects of ATP and UTP on TNAP activity are lost in P2Y2R
-/- osteoblasts 
In P2Y2R
+/+osteoblasts ATP (≥10µM) and UTP (≥1µM) reduce TNAP activity by up to 40%.  P2Y2R
-/- 
osteoblasts display basal TNAP activity levels that are up to 30% higher than wildtype cells.  The 
inhibitory effects of ATP and UTP on TNAP activity were lost in P2Y2R
-/- osteoblasts (Fig. 5C, 5D). 
The inhibitory effects of ATP and UTP on VSMC calcification and bone mineralisation are reduced 
in Enpp1-/- mice 
Since PPi mimics many of the actions of ATP and UTP we investigated whether the effects of these 
extracellular nucleotides involved P2 receptor independent mechanisms.  In Enpp1+/+ cells, ATP and 
UTP inhibit VSMC calcification from concentrations of 10µM and 1µM, respectively.  In Enpp1-/- VSMCs, 
ATP and UTP are 10-fold less potent only exerting inhibitory effects at 100µM and 10µM, respectively 
(Fig. 6A, 6B).    
Consistent with earlier studies, Enpp1-/- osteoblasts displayed increased levels of bone mineralisation 
compared to Enpp1+/+ cells (Anderson et al., 2005; Orriss et al., 2015). The inhibitory effects of ATP and 
UTP on bone mineralisation were 10-fold and 100-fold less potent, respectively, in Enpp1-/- osteoblasts 
(Fig. 6C, 6D).    
NPP1 deletion does not blunt the effects of ATP and UTP on cell viability and TNAP activity  
The protective effects of ATP and UTP on cell viability were unchanged in cultures of Enpp1-/- VSMCs 
(Fig. 7A, 7B).  Deletion of NPP1 also had no effect on the ATP/UTP-mediated increase in VSMC TNAP 
activity (Fig. 7C, 7D). 
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DISCUSSION 
This study compared the effects of extracellular nucleotides on AMC and bone mineralisation.  We found 
that, whilst the functional effect was the same, the cellular mechanisms mediating the observed inhibitory 
actions of ATP and UTP differed.  In VSMCs, ATP and UTP prevent calcification, at least in part, by 
reducing VSMC apoptosis.  In contrast, ATP and UTP have no effect on osteoblast survival and instead 
block bone mineralisation via the inhibition of TNAP.  Furthermore, the P2Y2 receptor does not appear to 
mediate the actions of ATP and UTP on AMC but is involved in the effects on bone mineralisation.  
However, NPP1-mediated generation of PPi contributes to the inhibitory effects observed in both VSMCs 
and osteoblasts (see summary Fig. 8). 
This study demonstrated, like others, that VSMCs express multiple P2X and P2Y receptor subtypes 
(Lewis and Evans, 2000; Wang et al., 2002). Consistent with earlier work that described protective 
effects of extracellular nucleotides on aortic valve calcification (Cote et al., 2012) and VSMC calcification 
(Villa-Bellosta and Sorribas, 2013), we also found that both ATP and UTP were inhibitory. UTP, which 
was more potent than ATP, only activates the P2Y2 and P2Y4 receptor subtypes.  Given the involvement 
of the P2Y2 receptor in inhibiting bone mineralisation (Fig. 5) (Hoebertz et al., 2002; Orriss et al., 2007), 
aortic valve calcification and intimal calcification (Cote et al., 2012; Qian et al., 2017), the P2Y2 receptor 
appeared to be a strong candidate for mediating the effects in VSMCs.  However, the effects of ATP and 
UTP on VSMC calcification were not lost in P2Y2R
-/- cells or blocked by a selective P2Y2 receptor 
antagonist.  Furthermore, P2Y2R
-/- VSMCs and aortic rings displayed no differences in the basal level of 
calcification in vitro and isolated aortas from 24-week old animals also showed no signs of AMC. It 
should be noted that aged animals were not studied here and so it is possible that the condition develops 
in older P2Y2R
-/- mice.  Taken together, these data suggest that ATP and UTP are not acting via the 
P2Y2 receptor to regulate AMC.   
Our findings contrast to previous work which has implicated the P2Y2 receptor in the effects of 
nucleotides on valve calcification (Cote et al., 2012) and arterial intimal calcification (Qian et al., 2017).  
There are a number of potential explanations for these observed differences.  Firstly, the lack of 
involvement of the P2Y2 receptor in aortic VSMCs could represent variation in the cellular mechanisms 
that underpin these different forms of pathological vascular calcification.  Secondly, it could be due to 
differences in the experimental models used since each investigation has utilised distinct in vitro and in 
vivo methods to study the different forms of vascular calcification.  Finally, given that the expression of 
functional P2 receptors is highly variable between cell types (Burnstock, 2007), it could also reflect a 
lower level of P2Y2 receptor expression in aortic VSMCs compared to valve interstitial cells or 
osteoblasts.  Interestingly, the mRNA expression of several P2 receptors including the P2Y2 receptor 
was upregulated in calcifying VSMCs compared to control cells.  Since the expression of P2 receptors by 
osteoblasts is differentiation dependent (Dixon et al., 1997; Noronha-Matos et al., 2012; Orriss et al., 
2006), this could reflect the changes in the VSMC phenotype which occur during the development of 
AMC. 
NPP1 hydrolyses extracellular ATP and UTP to produce the key local inhibitor of mineralisation, PPi.  
Since the effects of PPi on VSMC calcification mimicked those of ATP and UTP, we used Enpp1
-/- cells to 
determine the involvement of P2 receptor independent mechanisms. The effects of ATP and UTP were 
blunted in Enpp1-/- VSMCs and osteoblasts suggesting that NPP1-mediated hydrolysis to produce PPi 
does contribute to the observed inhibitory actions in both cell types. This is consistent with earlier work 
that examined the role of ATP-derived PPi in VSMC calcification (Prosdocimo et al., 2009; Prosdocimo et 
al., 2010) and bone formation (Orriss et al., 2013; Orriss et al., 2007).  However, since the effects were 
not completed attenuated it suggests that other mechanisms are also involved.  In osteoblasts, this is 
likely to be due to the P2 receptors that have been implicated in the regulation of bone mineralisation, 
such as the P2Y2, P2X1 and P2X7 receptors (Hoebertz et al., 2002; Orriss et al., 2012a; Orriss et al., 
2007). In VSMCs, the other mechanisms leading the functional effects are less clear.  Although unlikely 
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to be mediated by the P2Y2 receptor, involvement of other P2 receptor subtypes (e.g. the P2Y4 receptor) 
is probable and presents an area for future study.  Furthermore, since VSMCs have been shown to also 
express functional NPP3 (Prosdocimo et al., 2009), a role for other ecto-nucleotidases cannot be 
discounted. 
Increased VSMC apoptosis has been implicated in the development of vascular calcification (Proudfoot 
et al., 2000). In this study we found that, at the concentrations which inhibited calcification, ATP, UTP 
and PPi prevented the increase in apoptosis usually seen in calcifying VSMC cultures.  The effect of 
extracellular nucleotides on cell viability was unchanged in Enpp1-/- VSMCs.  This suggests that, 
although PPi itself appears to exert protective actions, ATP and UTP are working directly to promote 
VSMC survival in calcifying conditions.  Apoptosis is thought to promote calcification because the VSMC-
derived apoptotic bodies can act as a nucleation site for hydroxyapatite crystal formation (Proudfoot et 
al., 2000). Thus, the inhibitory effects of extracellular nucleotides (and PPi) on AMC could be mediated, 
at least in part, by their ability to reduce apoptosis. The overall result being that there are less apoptotic 
bodies on which calcification can be initiated. In contrast, extracellular nucleotides have no effect on 
osteoblast viability and so the inhibitory effects on bone mineralisation are not mediated via alterations in 
apoptosis. 
These differential effects of extracellular nucleotides on cell survival may also illustrate the differences 
between physiological bone mineralisation and pathological AMC.  Bone mineralisation is not associated 
with increased levels of osteoblast apoptosis and instead matrix vesicles are the primary nucleation site 
for hydroxyapatite formation (Anderson et al., 1975).  The initiation of AMC appears more heterogeneous 
with multiple factors acting as nucleation sites for calcification including apoptotic bodies and 
mineralisation-competent vesicles (Kapustin and Shanahan, 2012; Proudfoot et al., 2000).  
TNAP is a crucial enzyme in bone mineralisation, with deficiencies leading to hypophosphatasia a 
condition characterised by hypomineralisation and rickets (Caswell et al., 1991).  Increased TNAP 
expression and activity has also been associated with AMC (Narisawa et al., 2007; Sheen et al., 2015).  
Consistent with earlier work, we confirmed that ATP and UTP inhibited TNAP activity in osteoblasts 
(Orriss et al., 2007). We also demonstrated that this inhibition involved P2Y2 receptor activation since the 
effects on TNAP activity were lost in P2Y2R
-/- osteoblasts.  In contrast, at concentrations where 
calcification is inhibited by up to 80%, ATP and UTP stimulated VSMC TNAP activity. The reasons for 
this counterintuitive increase are unclear but since PPi, and to a lesser extent ATP and UTP, are 
hydrolysed by TNAP the higher substrate levels could lead to alterations in enzyme kinetics.  It is 
important to note that, even when stimulated, the TNAP activity of calcifying VSMCs was at least 100-
fold lower than that of mineralising osteoblasts in vitro. Taken together, our observations suggest two 
things; firstly, that whilst reduced TNAP activity contributes to the inhibition of bone mineralisation by 
ATP and UTP, alterations in TNAP activity are unlikely to mediate the functional effects of nucleotides on 
VSMC calcification.  Instead the effects on VSMC apoptosis appear to predominate. Secondly, although 
TNAP is essential for bone mineralisation its role in AMC appears more complex. 
It is widely accepted that the development of AMC shares similarities to physiological bone formation. 
Whilst the role of NPP1 was similar in both VSMCs and osteoblasts, this study demonstrated that there 
are also clear differences in the cellular mechanisms mediating the inhibitory effects of extracellular 
nucleotides.  This suggests that some of the underlying processes leading to AMC and bone 
mineralisation are not the same. It is these differences which need to be fully understood in order to 
identify a drug target or therapeutic agent that can prevent or regress AMC without exerting negative 
actions on the skeleton. 
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FIGURE LEGENDS 
Figure 1. The functional effects of extracellular nucleotides on VSMC calcification 
(A) VSMCs express mRNA for multiple P2 receptor subtypes; expression of the P2X1, P2X2, P2X4, 
P2X5, P2X6 and P2Y2 receptors is increased up to 3-fold in calcifying cells compared to control cells.  
(B) ATP and (C) UTP dose dependently (≥1µM) inhibit VSMC calcification by up to 80%.  (D) ADP and 
(E) UDP have no effect on VSMC calcification.  (F) PPi (≥10µM) reduces VSMC calcification by up to 
85%.  Values are mean ± SEM (n = 4 (mRNA only) or 6), * = p<0.05, ** = p<0.01, *** = p<0.001. (G) 
Representative light microscopy images of alizarin red stained VSMC cultures treated with extracellular 
nucleotides.  Scale bar = 50µm 
Figure 2.  ATP, UTP and PPi reduce VSMC cell death but have no effect on osteoblast survival 
(A) ATP, (B) UTP and (C) PPi dose dependently decrease the proportion of dead cells in calcifying 
VSMC cultures by up to 80%.   No effect of (D) ATP or (E) UTP on osteoblast viability. (F) PPi at the 
highest dose tested caused a small increase in the percentage of dead cells.  (G, H, I)  Culture of 
VSMCs in calcifying conditions was associated by an increased level of apoptosis (up to 2.3 fold).  ATP, 
UTP and PPi (≥10µM) reduced the amount of apoptosis to levels seen in non-calcifying cells. Values are 
mean ± SEM (n = 6), * = p<0.05, ** = p<0.01, *** = p<0.001.       
Figure 3.  Opposing effects of extracellular nucleotides on TNAP activity in VSMCs and 
osteoblasts 
(A)  ATP, (B) UTP and (C) PPi (≥1µM) increased VSMC TNAP activity by up to 88%.  (D) ATP and (E) 
UTP reduced osteoblast TNAP activity by up to 50%.  (F) No effect of PPi on osteoblast TNAP activity.  
Note that the basal levels of TNAP activity are approximately 100-fold higher in mineralising osteoblasts 
than calcifying VSMCs.  Values are mean ± SEM (n = 6), * = p<0.05, ** = p<0.01, *** = p<0.001.  
Figure 4.  Lack of involvement of the P2Y2 receptor in regulating AMC 
(A) Cultured VSMCs and (B) aortic rings from P2Y2R
-/- animals displayed no differences in the basal 
level of calcification.  The inhibitory effects of (C) ATP and (D) UTP were unchanged in P2Y2R
-/- VSMCs.  
(E)  The selective P2Y2 receptor antagonist, ARC118925XX, did not block the inhibitory effects of UTP 
on VSMC calcification.   (F)  Histological analysis of isolated aortas from 24-week old P2Y2R
-/- mice 
showed no difference in cell morphology or the presence of AMC.  Scale bar = 100µm.  The protective 
effects of (G) ATP and (H) UTP on cell viability were unaffected by deletion of the P2Y2 receptor.    The 
stimulatory actions of (I) ATP and (J) UTP on TNAP activity were unchanged in P2Y2R
-/- VSMCs.  Values 
are mean ± SEM (n = 6), * = p<0.05, ** = p<0.01, *** = p<0.001.      
Figure 5.  The role of the P2Y2 receptor in the inhibitory effects of ATP and UTP on bone 
mineralisation 
The inhibitory effects of (A) ATP and (B) UTP were reduced 10-fold and 100-fold, respectively, in P2Y2R
-
/- osteoblasts; mineralised bone nodule formation was 60% higher in P2Y2R
-/- osteoblasts. The inhibitory 
actions of (C) ATP and (D) UTP on TNAP activity were lost in P2Y2R
-/- osteoblasts.  Basal TNAP activity 
was increased up to 40% in P2Y2R
-/- cells.  Values are mean ± SEM (n = 6), * = p<0.05, ** = p<0.01, *** 
= p<0.001. Comparison of P2Y2R
+/+ to P2Y2R
-/-: # = p<0.05, ## = p<0.01, ### = p<0.001. (E)  
Representative whole well scans (unstained) and phase contrast microscopy images (alizarin red 
stained) showing the effects of ATP and UTP on bone mineralisation in P2Y2R
-/- and P2Y2R
+/+ 
osteoblasts. Areas of unmineralised matrix are highlighted by the arrows. Scale bars: whole well scans = 
0.5cm, microscopy images = 200µm. 
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Figure 6.  The actions of NPP1 contribute towards the inhibitory effects of ATP and UTP on VSMC 
calcification and bone mineralisation 
The inhibitory effects of (A) ATP and (B) UTP on calcification were reduced 10-fold in Enpp1-/- VSMCs. 
The decrease in bone mineralisation caused by (C) ATP and (D) UTP was 10-fold and 100-fold lower, 
respectively, in Enpp1-/- osteoblasts.  Values are mean ± SEM (n = 6), * = p<0.05, ** = p<0.01, *** = 
p<0.001. Comparison of Enpp1+/+ to Enpp1-/-:  # = p<0.05, ### = p<0.001. 
Figure 7.  The effect of ATP and UTP on VSMC survival and TNAP activity does not involve NPP1 
The protective effects of (A) ATP and (B) UTP on cell viability were unchanged in Enpp1-/- VSMCs. The 
stimulatory actions of (C) ATP and (D) UTP on TNAP activity were the same in Enpp1+/+ and Enpp1-/- 
cells.  Values are mean ± SEM (n = 6), * = p<0.05, *** = p<0.001.  
Figure 8.  Summary of the differing cellular mechanisms by which ATP and UTP exert their effects 
on AMC and bone mineralisation 
ATP and UTP inhibit AMC and bone mineralisation but there are some differences in the mechanisms 
mediating these actions.  In VSMCs (top), ATP and UTP act via P2 receptors to decrease apoptosis and, 
as a consequence, calcification.  In osteoblasts (OBs, bottom panel), ATP and UTP act via the P2Y2 
receptor to inhibit alkaline phosphatase (TNAP) activity. However, for both cell types hydrolysis of ATP 
and UTP to produce PPi by NPP1 also contributes to the inhibitory effects observed.  
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Table 1: Primer sequences for real time PCR 
Gene 
Primer sequence 
(5’-3’) 
 
P2X1 
S                              
AS 
tgt acg ggg aga aga acc tg              
tcc caa aca cct tga aga gg 
P2X2 
S                              
AS  
cgt ctt cat cgt gca gaa aa                      
cac ttt gtg ttc cga cat gg  
P2X3 
S                              
AS 
tac caa gtc ggt ggt tgt ga                        
cca ccc cac aaa gta gga ga 
P2X4 
S                              
AS 
gca ccc tcc acc atc tct aa                      
aaa cct ctt gcc aga agc aa 
P2X5 
S                              
AS 
ggg ctt tct tct gtg acc tg                          
gtt ggc ctc aac ctc aac at 
P2X6 
S                              
AS 
agc cat ggc ata aaa act gg                     
gtg aag ttc ttg gcc tga gc 
P2X7 
S                              
AS 
ggc act gga gga aaa ttt ga                         
tga gca agt caa tgc aca ca 
P2Y1  
S                              
AS 
agg aaa gct tcc agg agg ag                    
cgt gtc tcc att ctg ctt ga 
P2Y2  
S                              
AS 
gtc agc agt gac gac tca aga c             
tca gag gat atc agc ccc ttt a 
P2Y4 
S                              
AS 
agg aag cag cag aac acc at                   
caa gga gtc tgc act ggt ca 
P2Y6  
S                              
AS 
ttc cat ctt gca tga gac aga                      
gct tga aat cct cac ggt aga 
P2Y13 
S                              
AS 
ggc cac tag atg tca cct ttt c                     
gat ggt ggg gtg gta act aga a 
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